Cwm LLC Sells 776 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Cwm LLC reduced its stake in Vertex Pharmaceuticals by 10.1%, selling 776 shares and now holding 6,908 shares valued at approximately $3.08 million.
• Industry insiders have been active, with Director Bruce I. Sachs purchasing 5,000 shares for about $1.95 million, increasing his ownership by 12.50%.
• Vertex Pharmaceuticals reported a quarterly earnings of $4.52 per share, exceeding expectations, and set its full-year forecast with analysts anticipating an EPS of 15.63.

Cwm LLC lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 10.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,908 shares of the pharmaceutical company's stock after selling 776 shares during the quarter. Cwm LLC's holdings in Vertex Pharmaceuticals were worth $3,075,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Advisor OS LLC raised its stake in Vertex Pharmaceuticals by 4.4% during the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company's stock valued at $263,000 after purchasing an additional 23 shares during the period. Costello Asset Management INC raised its stake in Vertex Pharmaceuticals by 3.6% during the 2nd quarter. Costello Asset Management INC now owns 689 shares of the pharmaceutical company's stock valued at $307,000 after purchasing an additional 24 shares during the period. Avidian Wealth Enterprises LLC raised its stake in Vertex Pharmaceuticals by 2.1% during the 1st quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company's stock valued at $594,000 after purchasing an additional 25 shares during the period. Strategic Blueprint LLC raised its stake in Vertex Pharmaceuticals by 1.7% during the 1st quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company's stock valued at $726,000 after purchasing an additional 25 shares during the period. Finally, Newman Dignan & Sheerar Inc. raised its stake in Vertex Pharmaceuticals by 3.3% during the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company's stock valued at $350,000 after purchasing an additional 25 shares during the period. Institutional investors own 90.96% of the company's stock.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was bought at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Stock Up 2.0%

VRTX opened at $416.81 on Friday. The business has a fifty day moving average of $395.46 and a 200 day moving average of $436.76. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The stock has a market cap of $106.87 billion, a P/E ratio of 29.79 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. During the same quarter in the previous year, the business earned ($12.83) EPS. Vertex Pharmaceuticals's revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the topic of several recent analyst reports. Leerink Partnrs raised Vertex Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 25th. HC Wainwright decreased their target price on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating on the stock in a research note on Tuesday, August 5th. Leerink Partners upgraded Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and cut their price target for the company from $458.00 to $456.00 in a report on Thursday, September 25th. UBS Group set a $553.00 price target on Vertex Pharmaceuticals and gave the company a "buy" rating in a report on Tuesday, August 5th. Finally, Cantor Fitzgerald cut their price target on Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating for the company in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the company's stock. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $494.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.